Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.

Oncology - 1 Jan 2016

Huszno Joanna, Budryk Magdalena, Kołosza Zofia, Tęcza Karolina, Pamuła Piłat Jolanta, Nowara Elżbieta, Grzybowska Ewa

Abstract excerpt

OBJECTIVE: The suppressor gene CHEK2 encodes a cell cycle checkpoint kinase, involved in cell cycle regulation, apoptosis and response to DNA damage. The aim of this study was to analyze the differences between CHEK2 mutation carriers (CHEK2*1100delC/I157T) and noncarriers with respect to clinicopathological factors. METHODS: We reviewed the medical records of 100 early breast cancer patients (46 mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 2
Share to Family Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ki-67 Antigen

Share to Lymphatic Metastasis

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Trastuzumab

Source

Identifiers

PMID: 26991782
DOI: 10.1159/000444326

Genes

CHEK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.PMID 26991782Read ↗

Current perspectives on CHEK2 mutations in breast cancerSemantic proximity Read ↗

The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis.Semantic proximity Read ↗

Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association ConsortiumSemantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

The CHEK2 gene and inherited breast cancer susceptibility.Semantic proximity Read ↗

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.Semantic proximity Read ↗

The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.Semantic proximity Read ↗

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.Semantic proximity Read ↗

The risk of gastric cancer in carriers of CHEK2 mutations.Semantic proximity Read ↗

Prognostic Significance of CHEK2 Mutation in Progression of Breast CancerSemantic proximity Read ↗

Identification of CHEK2 Germline Mutations in BRCA1/2- and PALB2-Negative Breast and Ovarian Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.